Identification of Key Gene Related to Matrisome in HBV-Associated Liver Cirrhosis via Bioinformatics Analysis

通过生物信息学分析鉴定乙型肝炎病毒相关肝硬化中与基质组相关的关键基因

阅读:1

Abstract

Background: Hepatitis B virus (HBV)-associated liver cirrhosis, characterized by progressive fibrosis and regenerative nodule formation, remains a critical public health concern due to its high risk of progression to hepatocellular carcinoma (HCC). The matrisome-comprising extracellular matrix (ECM) components such as collagens, laminins, fibronectin, glycoproteins, and proteoglycans-plays a pivotal role in disease pathogenesis. Previous studies have shown that HBV infection modulates ECM composition and activates fibrogenic responses through hepatic stellate cells, contributing to cirrhosis and eventual HCC development. However, key ECM-related genes driving HBV-induced cirrhosis remain poorly understood. Methods: Bulk RNA-seq data from 30 normal and 30 HBV-related cirrhotic liver tissues were analyzed. Differentially expressed genes (DEGs) were identified using the Limma package based on thresholds of p < 0.01 and |log2 fold change| > 1. ECM-related genes were curated from the Molecular Signatures Database (MsigDB). Functional significance was assessed via random forest classification (accuracy: 91%, recall: 90%), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Results: Among 14,470 analyzed genes, 2125 were upregulated and 3689 downregulated in cirrhotic tissues. Upregulated genes (COX6B1, RPS10) were linked to metabolic reprogramming, while downregulated genes (PLCG2, ARHGEF12) implicated immune dysregulation. A subset of 274 ECM-related DEGs (178 upregulated, 96 downregulated) was identified, including CTSA, CRELD2, MAPK10, and ITGA1. Pathway analysis highlighted dysregulation of Ras/MAPK and ERBB signaling pathways associated with fibrogenesis and tumorigenesis. Conclusions: This bioinformatics study delineates key matrisome-associated genes and pathways in HBV-related cirrhosis, offering novel insights into potential biomarkers and therapeutic targets. Further validation in larger cohorts is warranted to confirm clinical relevance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。